Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas C Shea

Showing results (21-30 of 80) with videos related to

Pageof 8
Sort By:
Ebiomedicine|September 5, 2016
Chemotherapy and Stem Cell Transplantation Increase p16<sup>INK4a</sup> Expression, a Biomarker of T-cell AgingWilliam A Wood, Janakiraman Krishnamurthy, Natalia Mitin, et al.
Blood Advances|June 10, 2020
ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphomaSteven I Park, Thomas C Shea, Oludamilola Olajide, et al.
Blood|March 31, 2012
Meeting the challenge of hematologic malignancies in sub-Saharan AfricaSatish Gopal, William A Wood, Stephanie J Lee, et al.
American Journal of Hematology|November 1, 2002
Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemiaHendrik W van Deventer, Melissa D Hall, Robert Z Orlowski, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 18, 2020
Evaluation of mobilization efficacy with an extended interval following plerixafor administrationSarah E Stump, Morgan Trepte, J Ryan Shaw, et al.
The Analyst|November 3, 2015
Microfluidics for the detection of minimal residual disease in acute myeloid leukemia patients using circulating leukemic cells selected from bloodJoshua M Jackson, James B Taylor, Małgorzata A Witek, et al.
Leukemia & Lymphoma|April 10, 2009
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survivalThomas C Shea, Anne W Beaven, Dominic T Moore, et al.
Journal of Healthcare Management / American College of Healthcare Executives|July 4, 2014
Assessing the feasibility of a virtual tumor board program: a case studyChristopher M Shea, Randall Teal, Lindsey Haynes-Maslow, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 27, 2015
Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant PatientsThomas C Shea, Christine Walko, Yunro Chung, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 19, 2003
An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignanciesThomas C Shea, Rebecca Bruner, Joseph M Wiley, et al.
Pageof 8

Showing results (21-30 of 80) with videos related to

Sort By:
Pageof 8
Ebiomedicine|September 5, 2016
Chemotherapy and Stem Cell Transplantation Increase p16<sup>INK4a</sup> Expression, a Biomarker of T-cell AgingWilliam A Wood, Janakiraman Krishnamurthy, Natalia Mitin, et al.
Blood Advances|June 10, 2020
ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphomaSteven I Park, Thomas C Shea, Oludamilola Olajide, et al.
Blood|March 31, 2012
Meeting the challenge of hematologic malignancies in sub-Saharan AfricaSatish Gopal, William A Wood, Stephanie J Lee, et al.
American Journal of Hematology|November 1, 2002
Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemiaHendrik W van Deventer, Melissa D Hall, Robert Z Orlowski, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 18, 2020
Evaluation of mobilization efficacy with an extended interval following plerixafor administrationSarah E Stump, Morgan Trepte, J Ryan Shaw, et al.
The Analyst|November 3, 2015
Microfluidics for the detection of minimal residual disease in acute myeloid leukemia patients using circulating leukemic cells selected from bloodJoshua M Jackson, James B Taylor, Małgorzata A Witek, et al.
Leukemia & Lymphoma|April 10, 2009
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survivalThomas C Shea, Anne W Beaven, Dominic T Moore, et al.
Journal of Healthcare Management / American College of Healthcare Executives|July 4, 2014
Assessing the feasibility of a virtual tumor board program: a case studyChristopher M Shea, Randall Teal, Lindsey Haynes-Maslow, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 27, 2015
Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant PatientsThomas C Shea, Christine Walko, Yunro Chung, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 19, 2003
An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignanciesThomas C Shea, Rebecca Bruner, Joseph M Wiley, et al.
Pageof 8